Federal Byetta Lawsuit Litigation Schedules First Status Conference, State Court Case Heads to Trial in November
The growing nationwide litigation of Januvia and Byetta lawsuit claims is continuing to pick up speed with the scheduling of a status conference in a federal proceeding involving incretin mimetics, and a California state court trial slated to begin this November, according to reports.
In the federal litigation established just last month in the U.S. District Court, Southern District of California, an Initial Conference will be held on October 17th to discuss matters related to Byetta and Januvia lawsuit claims alleging a connection between the class of type-2 diabetes medications and pancreatitis, pancreatic cancer and possibly thyroid cancer. An Order issued on September 11th indicates that at least 60 claims have been filed in the proceeding. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
Trial Start Date for Byetta Lawsuit Scheduled for November
A Byetta lawsuit has already been scheduled for trial in California state court in Los Angeles. This case was filed on behalf of seven individuals who allegedly developed pancreatitis after taking the incretin mimetic manufactured by Amylin Pharmaceuticals. According to the suit, two of the plaintiffs died of complications caused by the medication.
Byetta lawyers have reported that an expert in diabetes research and the side effects of incretin mimetics from the University of Bristol in the UK is expected to testify on the plaintiffs’ behalf during the trial.
Byetta Pancreatic Cancer Concerns Grow Since 2008
Concerns about Byetta cancer and other side effects have grown steadily since 2008, when the U.S. Food and Drug Administration (FDA) issued its first warning about the drug’s connection to pancreatitis. The 2008 alert noted the medication’s association with pancreatitis, a risk factor for pancreatic cancer. On March 14, 2013, Byetta was further scrutinized after the findings of an unpublished study linked Byetta to pre-cancerous cellular changes in the pancreas. This condition is referred to as pancreatic duct metaplasia.
The Institute for Safe Medicine Practices published a statistic shortly after that showed individuals who took incretin mimetics may be 25 times more likely to develop pancreatic cancer than those who took other diabetes medications.
How to File a Byetta or Januvia Lawsuit
For more information about Byetta and Januvia pancreatic cancer lawsuits, contact an attorney at Bernstein Liebhard LLP to file a claim. The Firm can be reached at (877) 779-1414.